0001209191-23-050874.txt : 20230929
0001209191-23-050874.hdr.sgml : 20230929
20230929172734
ACCESSION NUMBER: 0001209191-23-050874
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230630
FILED AS OF DATE: 20230929
DATE AS OF CHANGE: 20230929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Sanjiv
CENTRAL INDEX KEY: 0001816210
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39385
FILM NUMBER: 231296800
MAIL ADDRESS:
STREET 1: C/O RELAY THERAPEUTICS, INC.
STREET 2: 399 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Relay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001812364
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-370-8837
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-06-30
0
0001812364
Relay Therapeutics, Inc.
RLAY
0001816210
Patel Sanjiv
C/O RELAY THERAPEUTICS, INC.
399 BINNEY STREET, 2ND FLOOR
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
0
Common Stock
2023-06-30
5
A
0
E
1662
10.68
A
1662
D
Common Stock
674548
I
By The Patel Family Irrevocable Trust of 2019
Common Stock
687355
I
By The SSP Irrevocable Trust of 2020
The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023.
These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Brian Adams, as attorney-in-fact
2023-09-29